Breast cancer-related lymphedema (BCRL) is a frequent and burdensome complication of oncologic treatment with substantial impact on physical, functional, and psychosocial well-being. The LYMPH-Q Upper Extremity Module is a validated, lymphedema-specific patient-reported outcome measure (PROM) designed to evaluate lymphedema severity and quality of life among patients with arm lymphedema. To date, no translated and culturally adapted French version is available. As part of the LYMPH trial, we conducted a structured translation and cross-cultural adaptation of the LYMPH-Q Upper Extremity Module into French following the Q-Portfolio Translation and Cultural Adaptation Guidelines, in alignment with the ISPOR and COSMIN recommendations. The translation process involved the following steps: dual forward translation, reconciliation, back translation, expert back translation review, and cognitive debriefing interviews with French-speaking patients. The translations were then adjusted based on patient feedback. Five French-speaking women with unilateral BCRL participated in cognitive debriefing interviews. Overall, the French LYMPH-Q was well understood, with only minor wording and phrasing adjustments identified for selected items. Fourteen linguistic refinements were noted across the Symptoms, Function, Information, and Arm Sleeve scales. All discrepancies were resolved through targeted modifications, without altering the underlying constructs of the original instrument. The French version of the LYMPH-Q Upper Extremity Module demonstrated satisfactory linguistic and cultural acceptability among Swiss French-speaking patients and provides an important step toward implementing PROMs in French-speaking patients with upper extremity lymphedema.
Introduction: Chronic seroma and pseudomeningocele formation following spinal instrumentation, particularly in the setting of prior infection and multiple revision surgeries, remains rare but pose a significant therapeutic challenge due to high recurrence rate. In this context, we present a complex case of pseudomeningocele that evolved into a persistent seroma with cutaneous fistula after multi-level lumbar fusion with a comprehensive review of sclerotherapy protocols. Materials and methods: A 75-year-old patient with prior L3-S1 fusion surgery presented with rod fracture and underwent surgical revision. Postoperatively, a collection with purulent discharge and altered consciousness raised suspicion of a dural breach, later confirmed by Beta-Trace protein testing. Despite multiple revisions and placement of a pedicled SGAP flap, persistent pseudomeningocele developed, evolving in a chronic seroma after CSF leak resolution. The course was further complicated with chronic Staphylococcus Epidermidis infection. Revision surgery with flap mobilization and capsulectomy failed to resolve the seroma. Due to limited surgical options, a multi-instillation doxycycline sclerotherapy protocol via radiologically guided drain was initiated. Results: The sclerotherapy protocol resulted in progressive decrease in drain output, ultimately allowing for drain removal after 34 days. Follow-up ultrasound 7 days and 3 months after drain removal showed no significant fluid collection. No recurrence of fistula or seroma was observed during follow-up. Conclusion: This case highlights the challenges of managing postoperative wound complications in spinal surgery, particularly in the context of prior infection, hardware exposure, and suspected cerebrospinal fluid leak. A pedicled SGAP flap provided durable coverage, and doxycycline sclerotherapy proved an effective salvage treatment for persistent seroma after unsuccessful surgical revision.
1 September 2026 in Plastic and Reconstructive Surgery - Global Open
Background: Seroma at the abdominal donor site is a recognized complication following deep inferior epigastric perforator (DIEP) flap breast reconstruction. Reported incidences vary widely, reflecting differences in surgical technique, patient characteristics, and outcome reporting. Consequently, this proportional meta-analysis aims to estimate the pooled incidence of abdominal donor-site seroma and evaluate potential risk factors associated with its occurrence. Methods: A systematic literature review of PubMed, Web of Science, and the Cochrane Library was performed up to June 2025. Studies reporting abdominal donor-site seroma rates following DIEP flap reconstruction were included. Data were pooled using a random-effects model (DerSimonian–Laird), and heterogeneity was assessed using I2 and τ 2 statistics. Univariable meta-regression analyses explored associations of smoking status and diabetes with seroma occurrence. Results: The search identified 1345 unique records, of which 71 studies met the inclusion criteria, comprising 12,739 patients and 16,915 DIEP flaps. A total of 736 seromas were reported, yielding a pooled incidence of 6% (95% confidence interval, 4%–7%). Heterogeneity was substantial ( I2 = 85.3%, τ 2 = 0.05, P < 0.001). The mean body mass index and age were 27.2 kg/m 2 and 50.4 years, respectively. Meta-regression showed no significant association between seroma occurrence and smoking ( P = 0.57) or diabetes ( P = 0.07). Conclusions: Donor-site seroma occurs in 6% of DIEP flap reconstructions. The absence of associations with smoking or diabetes in meta-regression suggests that seroma formation may be influenced by technical and perioperative factors rather than by comorbidities.